![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1417482
¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ±â¼ú ½ÃÀå : µ¿Çâ, ¿¹Ãø, °æÀï ºÐ¼®(-2030³â)Pharmacogenomics Technology Market Report: Trends, Forecast and Competitive Analysis to 2030 |
¾à¹°À¯ÀüüÇÐ ±â¼úÀÇ µ¿Çâ°ú ¿¹Ãø
¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ±â¼ú ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁöÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 6.7%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç 2030³â±îÁö ÃßÁ¤ 124¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº À¯ÀüüÇÐ ºÐ¾ß¿¡¼ À¯ÀüÀÚ Â÷ÀÌÀÇ ÇØ¸í°ú ¾à¹° ¹ÝÀÀ¼º¿¡ ¹ÌÄ¡´Â ¿µÇâÀÇ ´ëÆøÀûÀÎ ÁøÀü, ¸¸¼º Áúȯ Áõ°¡¿¡ ÀÇÇÑ ¸ÂÃãÇü Ä¡·áÀÇ ¿ä±¸ Áõ°¡, °Ô³ð ½ÃÄö½ÌÀÇ ºñ¿ë ÀúÇÏ ±×¸®°í ±â¼úÀÇ Áøº¸ÀÔ´Ï´Ù. ¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ±â¼ú ½ÃÀåÀÇ ¹Ì·¡´Â Á¾¾ç, ½Å°æ Áúȯ, ¼øÈ¯±â Áúȯ, ¸é¿ª Áúȯ, °¨¿°Áõ ½ÃÀå¿¡ ±âȸ°¡ ÀÖ°í À¯¸Á½ÃµÇ°í ÀÖ½À´Ï´Ù.
¾à¹°À¯ÀüüÇÐ ±â¼ú ½ÃÀå ÀλçÀÌÆ®
LucintelÀº PCRÀÌ Æ¯Á¤ DNA ¼¿ÀÇ ÁõÆøÀ» °¡´ÉÇÏ°Ô Çϱ⠶§¹®¿¡ À¯ÀüÀÚÇü ÆÇÁ¤À̳ª ¾à¹° ¹ÝÀÀ°ú °ü·ÃµÈ À¯ÀüÀÚ º¯ÀÌÀÇ °áÁ¤¿¡ ÇʼöÀûÀÎ µµ±¸À̸ç, ¾àÈ¿³ª ´ë»ç¿¡ ¿µÇâÀ» ÁÖ´Â À¯ÀüÀÚ º¯È³ª ÀÏ¿°±â ´Ù À¯Çü(SNP)À» ã´Â µ¥ ÀÚÁÖ »ç¿ëµÇ±â ¶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ºÎ¹®ÀÌ °è¼Ó µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ºÏ¹Ì´Â ÀÌ ºÐ¾ß¿¡¼ À¯¸íÇÑ ±â¾÷ÀÇ Á¸Àç, À¯¸®ÇÑ º¸Çè»óȯ±ÔÄ¢, Ä¡·á°³¼±À» À§ÇÑ Á¶±âÁø´ÜÀÇ Á߿伺¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö¸ç, ÀÌ Áö¿ªÀÇ Á¤ºñµÈ ÇコÄɾî ÀÎÇÁ¶ó µîÀÇ ÀÌÀ¯·Î ¿¹Ãø±â°£ Áß ½ÉÁö¾î °¡Àå ±Ô¸ð°¡ Å« Áö¿ªÀ¸·Î °è¼Ó µÉ °Í °°½À´Ï´Ù.
Q1. ½ÃÀå ±Ô¸ð´Â?
A1. ¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ±â¼ú ½ÃÀåÀº 2030³â±îÁö ¿¹»ó 124¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Q2. ½ÃÀåÀÇ ¼ºÀå ¿¹ÃøÀº?
A2. ¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ±â¼ú ½ÃÀåÀº 2024³âºÎÅÍ 2030³â¿¡ °ÉÃÄ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 6.7%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
Q3. ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº?
A3. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº À¯ÀüüÇÐ ºÐ¾ß¿¡¼ÀÇ À¯ÀüÀû Â÷ÀÌÀÇ ÇØ¸í°ú ±×°ÍÀÌ ¾à¹°¹ÝÀÀ¼º¿¡ ¹ÌÄ¡´Â ¿µÇâÀÇ ´ëÆøÀûÀÎ ÁøÀü, ¸¸¼ºÁúȯ Áõ°¡¿¡ ÀÇÇÑ ¸ÂÃãÇü Ä¡·áÀÇ ¿ä±¸ Áõ°¡, °Ô³ð ½ÃÄö½ÌÀÇ ºñ¿ë ÀúÇÏ¿Í ±â¼úÀÇ Áøº¸ÀÔ´Ï´Ù.
Q4. ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº?
A4. ¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ±â¼ú ½ÃÀåÀÇ ¹Ì·¡´Â Á¾¾ç, ½Å°æÁúȯ, ¼øÈ¯±âÁúȯ, ¸é¿ªÁúȯ, °¨¿°Áõ½ÃÀå¿¡ ±âȸ°¡ ÀÖ¾î À¯¸ÁÇÕ´Ï´Ù.
Q5. ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?
A5. ÁÖ¿ä ¾à¹°À¯ÀüüÇÐ ±â¼ú ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.
Q6. ¾ÕÀ¸·Î °¡Àå Å« ½ÃÀå ºÎ¹®Àº?
A6.LucintelÀº PCRÀº ƯÁ¤ DNA ¼¿ÀÇ ÁõÆøÀ» °¡´ÉÇÏ°Ô Çϰí, À¯ÀüÀÚÇü ÆÇÁ¤À̳ª ¾à¹° ¹ÝÀÀ°ú °ü·ÃµÈ À¯ÀüÀÚ º¯ÀÌÀÇ °áÁ¤¿¡ ÇʼöÀûÀÎ ÅøÀ̸ç, ¾àÈ¿³ª ´ë»ç¿¡ ¿µÇâÀ» ÁÖ´Â À¯ÀüÀÚ º¯È³ª ÀÏ¿°±â ´Ù À¯Çü(SNP)À» ã´Â µ¥ ÀÚÁÖ »ç¿ëµÇ±â ¶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ºÎ¹®ÀÌ °è¼Ó µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Q7. ½ÃÀå¿¡¼ ÇâÈÄ 5³â°£ ÃÖ´ë°¡ µÉ °ÍÀ¸·Î ¿¹»óµÇ´Â Áö¿ªÀº?
A7. ºÏ¹Ì´Â ÀÌ ºÐ¾ß¿¡¼ À¯¸íÇÑ ±â¾÷ÀÇ Á¸Àç, À¯¸®ÇÑ »óȯ±ÔÄ¢, Ä¡·á°³¼±À» À§ÇÑ Á¶±âÁø´ÜÀÇ Á߿伺¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í, ÀÌ ºÐ¾ßÀÇ ÇコÄɾî ÀÎÇÁ¶ó°¡ ¹ß´ÞÇϰí ÀÖ´Â °Í µîÀ¸·ÎºÎÅÍ ¿¹Ãø ±â°£À» ÅëÇØ °¡Àå ±Ô¸ð°¡ Å« Áö¿ªÀ¸·Î °è¼Ó µÉ °ÍÀÔ´Ï´Ù.
Q8. º¸°í¼ÀÇ Ä¿½ºÅ͸¶ÀÌÁî´Â °¡´É?
A8. ±×·¸½À´Ï´Ù, Lucintel´Â Ãß°¡ ºñ¿ë ¾øÀÌ 10% ÁÖ¹®À» ¹Þ¾Æ¼ ¸¸µì´Ï´Ù.
Pharmacogenomics Technology Trends and Forecast
The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market. The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030 with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.
A more than 150-page report is developed to help in your business decisions.
Pharmacogenomics Technology by Segment
The study includes a forecast for the global pharmacogenomics technology by technology, therapeutic area, and region.
List of Pharmacogenomics Technology Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pharmacogenomics technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pharmacogenomics technology companies profiled in this report include-
Pharmacogenomics Technology Market Insights
Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.
North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.
Features of the Global Pharmacogenomics Technology Market
Market Size Estimates: Pharmacogenomics technology market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Pharmacogenomics technology market size by technology, therapeutic area, and region in terms of value ($B).
Regional Analysis: Pharmacogenomics technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different technology, therapeutic area, and regions for the pharmacogenomics technology market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pharmacogenomics technology market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the pharmacogenomics technology market size?
Answer: The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030.
Q2. What is the growth forecast for pharmacogenomics technology market?
Answer: The global pharmacogenomics technology market is expected to grow with a CAGR of 6.7% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the pharmacogenomics technology market?
Answer: The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.
Q4. What are the major segments for pharmacogenomics technology market?
Answer: The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market.
Q5. Who are the key pharmacogenomics technology market companies?
Answer: Some of the key pharmacogenomics technology companies are as follows.
Q6. Which pharmacogenomics technology market segment will be the largest in future?
Answer: Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.
Q7. In pharmacogenomics technology market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.